Jörtsö E, Tegler L, Smeds S
Acta Endocrinol Suppl (Copenh). 1987;281:115-7. doi: 10.1530/acta.0.114s115.
Human toxic diffuse goitre tissue was xenotransplanted to athymic mice. Transplant function was analyzed as 18 h [125I]thyroid transplant uptake at day 21 and at 10 weeks after transplantation. Graves' IgG or normal IgG was given ip daily day 22-35. Epithelial cell proliferation in the thyroid transplants was analyzed by continuous [3H]thymidine administration for 12 days between day 28 and 39 in a separate series given Graves' or normal IgG daily during the same period. The 18 h transplant uptake increased 12.8 times from 3 to 10 weeks in the Graves' IgG group but only 3.6 times in the controls (P less than 0.05). The fraction of labelled cells after [3H]thymidine incorporation was 51% +/- (SEM) after parallel Graves' IgG administration but only 2 +/- 0.3% (P less than 0.002) in the controls. The increased 10 weeks iodide uptake after Graves' IgG may be explained by an increased vascularisation or capillary maturation, by an increased individual cell sensitivity to stimulation or by an increased number of cells. Our results indicate that serum from patients with toxic diffuse goitre, i.e. Graves' IgG, contains a factor which promotes thyroid epithelial cell proliferation. Whether this is identical to TSI or is another IgG fraction remains to be shown.
将人类毒性弥漫性甲状腺肿组织异种移植到无胸腺小鼠体内。在移植后第21天和第10周，通过18小时[125I]甲状腺移植摄取量分析移植功能。在第22 - 35天每天腹腔注射格雷夫斯病患者的IgG或正常IgG。在另一个系列中，在第28天至39天期间，连续12天给予[3H]胸腺嘧啶核苷，分析甲状腺移植中的上皮细胞增殖情况，在此期间每天给予格雷夫斯病患者的IgG或正常IgG。格雷夫斯病患者的IgG组中，18小时移植摄取量从3周增加到10周时增加了12.8倍，而对照组仅增加了3.6倍（P < 0.05）。在平行给予格雷夫斯病患者的IgG后，[3H]胸腺嘧啶核苷掺入后的标记细胞比例为51%±（标准误），而对照组仅为2±0.3%（P < 0.002）。格雷夫斯病患者的IgG作用后10周碘摄取量增加，可能是由于血管生成增加或毛细血管成熟、单个细胞对刺激的敏感性增加或细胞数量增加所致。我们的结果表明，毒性弥漫性甲状腺肿患者的血清，即格雷夫斯病患者的IgG，含有促进甲状腺上皮细胞增殖的因子。这是否与甲状腺刺激免疫球蛋白相同或是否为另一种IgG组分尚待确定。
